Ciprofol exerts anti-tumour effects in hepatocellular carcinoma through the Raf-MEK-ERK signalling pathway

作者：Yining Chen, Ping Shi, Suiqing Zhou, Kai Yu, Y.M. Wang, Feifan Yao, Ruizhi Zhang, Xin‐Yang Liu, Chunyao Fang, Xiaofeng Tie, Jun Li, Jing Xu, Jiali Xu, Xiongxiong Pan · 发表于：Translational Gastroenterology and Hepatology · 年份：2025 · DOI：10.21037/tgh-24-115 · 被引用次数：2 · 研究领域：Cancer, Stress, Anesthesia, and Immune Response、Cell death mechanisms and regulation、Hepatocellular Carcinoma Treatment and Prognosis

Background: Hepatocellular carcinoma (HCC) is one of the most prevalent malignant tumours of the digestive system and the third leading cause of cancer-related deaths worldwide. As the most common type of primary liver cancer, HCC is associated with poor prognosis despite advancements in treatment options such as radical resection, liver transplantation, and adjuvant therapies. Surgical resection remains the cornerstone of HCC treatment; however, postoperative recurrence and metastasis pose significant challenges to patient survival. Intraoperative factors, including immune suppression and the use of certain anaesthetics, have been implicated in tumour cell dissemination and recurrence. While anaesthetic agents like propofol are known to influence tumour cell proliferation, differentiation, and apoptosis. Ciprofol, a novel intravenous anaesthetic, has demonstrated clinical safety and efficacy, but its potential impact on HCC progression and underlying mechanisms requires further exploration. This study aims to explore how ciprofol affects the behaviour of HCC cells and the underlying mechanisms. Methods: , and a lung metastasis model was created to examine its effects on metastasis. RNA sequencing (RNA-seq) identified transcriptional changes after ciprofol treatment, and western blot and immunofluorescence (IF) validated these findings. Results: Ciprofol inhibited the proliferation, migration, and invasion of Hep3B and HCCLM3 cells in a manner dependent on both time and dosag...